Globus Medical, Inc. (GMED) - Deep Dive Research Report

Healthcare / Medical Devices - Musculoskeletal Solutions and Surgical Enabling Technology Report date: June 20, 2026

1. What the Company Does

Globus Medical makes the hardware that surgeons screw, plug, and bolt into the human skeleton. When a person has two vertebrae fused together to stop chronic back pain, the titanium screws, the rods that connect them, and the cage that sits in the gap where the worn-out disc used to be are very often made by Globus. The company designs, manufactures, and sells these implants, plus the disposable instruments used to put them in, plus, increasingly, the robots and imaging systems that guide the surgeon's hand while doing it.

The core of the business is spine surgery. A spinal fusion is a high-stakes, technically demanding procedure where millimeters matter: a pedicle screw placed a few degrees off can hit a nerve root or breach the spinal canal. Globus sells the surgeon a complete kit for that operation, and then sells a refill of single-use implants and consumables every time the surgeon does another case. The economics resemble razor-and-blade: the relationship is won once, at the surgeon level, and then it recurs case after case for years.

Globus was founded in 2003 in Audubon, Pennsylvania by David Paul, an engineer who had previously worked at Synthes (the dominant trauma and spine company later bought by Johnson & Johnson). Paul built Globus into one of the fastest-growing spine companies of the 2000s and 2010s by being aggressive on product iteration - pushing out new implant systems faster than the incumbents - and by recruiting surgeon-loyal sales reps away from competitors. The company went public in 2012. Paul handed the CEO role to David Demski in 2017 and became Executive Chairman, the position he still holds as the founder and a major shareholder.

Two acquisitions define the company you see today:

• NuVasive (September 2023, ~$3.1 billion all-stock). This was the transformative deal. NuVasive was Globus's roughly equal-sized rival in spine, the pioneer of "minimally invasive" lateral-approach spine surgery (the XLIF procedure). Overnight, Globus roughly doubled in size and became the clear number-two player in global spine behind Medtronic. It also inherited NuVasive's specialized orthopedics unit (magnetically adjustable growing rods for children with scoliosis, and limb-lengthening systems) and NuVasive's own robotics/navigation platform (Pulse).
• Nevro (April 2025, ~$250 million). A much smaller, opportunistic deal. Nevro makes spinal cord stimulators (implanted devices that deliver electrical pulses to mask chronic pain signals, used for failed back surgery and painful diabetic neuropathy). This pushed Globus into the adjacent neuromodulation / chronic-pain market. Nevro was a struggling standalone company; Globus bought it cheap and is restructuring it.

The value proposition has two layers. To the surgeon: a broad, constantly refreshed catalogue of implants plus a robot (ExcelsiusGPS) that makes screw placement faster, more reproducible, and less radiation-heavy, with a salesperson in the room for every case. To the hospital: a single vendor that can supply almost the entire spine-and-musculoskeletal shopping list, which simplifies purchasing contracts. The thing that is genuinely hard to replicate is not any single implant - those get copied - it is the installed base of robots (around 130,000 robotic procedures completed to date) plus the surgeon relationships plus the manufacturing scale to iterate product lines quickly while holding regulatory clearances across dozens of systems.

"U.S. spine has now grown double digits for the third consecutive quarter, with 58 weeks of consecutive growth, driven primarily by market share gains." - Keith Pfeil, CEO, Q1 2026 call (May 7, 2026)

2. Business Segments

Globus reports in two segments, but the split is lopsided: one is almost the entire company by revenue, the other is small by revenue but strategically central because it pulls the first one along.

Musculoskeletal Solutions (~96% of revenue)

This is the implant business. In Q1 2026 it produced roughly $733 million of the company's ~$760 million in sales. It contains everything that gets implanted or consumed in a procedure:

• Spine - the heart of it. Pedicle screw systems, rods, interbody cages (the spacers that replace a degenerated disc), expandable cages, cervical (neck) plates and discs, and the disposable instruments. This is split into US Spine (the engine, growing double digits on share gains) and International Spine (EMEA and Latin America the strongest geographies).
• Trauma - plates, screws, and nails for broken bones, plus the ANTHEM elbow system. A smaller but fast-growing line (Q1 2026 trauma grew ~30%).
• NuVasive Specialized Orthopedics (NSO) - inherited from NuVasive. MAGEC magnetically-adjustable growing rods for pediatric scoliosis (lengthened non-invasively with an external magnet as the child grows) and the Precice limb-lengthening system. A genuinely differentiated, hard-to-copy niche.
• Regenerative biologics - bone graft materials and biologics that promote fusion.
• Interventional pain / neuromodulation (Nevro) - the HFX spinal cord stimulation platform (Senza system) for chronic trunk/limb pain and painful diabetic neuropathy. Contributed ~$83 million in Q1 2026 and is being restructured.

The core capability here is breadth plus iteration speed. Globus has historically been able to take an implant concept from idea to FDA-cleared product faster than the larger incumbents, and to maintain a catalogue wide enough that a surgeon rarely needs a second vendor. The NuVasive deal added the lateral-access franchise (XLIF) and the pediatric/limb-lengthening know-how, both of which would take years to build organically. This segment is the margin engine and the cash cow: it is where the recurring, high-gross-margin implant revenue lives.

Enabling Technologies (~4% of revenue)

This is the robotics, navigation, and imaging hardware business - around $27 million in Q1 2026. The flagship is ExcelsiusGPS, a surgical robot combined with navigation that guides pedicle-screw placement. Alongside it sit Excelsius3D (a mobile intraoperative imaging system), the Excelsius Hub, and the inherited NuVasive Pulse platform. The company also recently received FDA clearance for orthopedic-reconstruction robotics, extending the platform beyond spine.

By revenue this segment is tiny and lumpy (capital equipment deals close in big, irregular chunks, and a single soft quarter on deal closures can swing the number). But its strategic weight is far larger than its revenue. Every robot or imaging system placed in a hospital is a magnet that pulls implant sales toward Globus: once a surgeon is doing cases on an ExcelsiusGPS, the path of least resistance is to use Globus implants designed to integrate with it. Management is now deliberately shifting this segment away from big upfront capital sales toward lease and rental models, trading near-term equipment revenue for recurring implant and service pull-through. So the right way to think about Enabling Technologies is as customer-acquisition infrastructure for the Musculoskeletal segment, not as a standalone profit center.

3. Products and Business Detail

The product catalogue is deep, and the depth is itself the point - a surgeon can run almost an entire practice on Globus hardware.

Spine implants. Posterior fixation (CREO and REVERE pedicle-screw systems and their successors), interbody devices including static and expandable cages (an expandable cage is inserted small and then expanded in situ to restore disc height, reducing the trauma of insertion), cervical plates and motion-preserving cervical discs, and the lateral-access interbody systems inherited from NuVasive (the XLIF franchise, where the spine is approached from the patient's side through the psoas muscle rather than from the front or back). A notable recent launch is SCRIPT - patient-specific, additively manufactured (3D-printed) lumbar spacers and rods, patient-matched to the individual's anatomy and integrated with ExcelsiusGPS navigation, which received early FDA clearances in Q2 2026.

Trauma and extremities. Plating and nailing systems for fractures, plus the ANTHEM total elbow.

NuVasive Specialized Orthopedics (NSO). MAGEC growing rods and Precice limb-lengthening - both magnetically driven internal devices, a technically distinct and well-protected niche.

Regenerative biologics. Bone-graft substitutes and biologic scaffolds that encourage bone to bridge across a fusion.

Neuromodulation (Nevro HFX / Senza). Implantable pulse generators and leads delivering high-frequency (10 kHz) spinal cord stimulation for chronic pain, including an FDA indication for painful diabetic neuropathy.

Enabling Technologies hardware. ExcelsiusGPS (robot + navigation), Excelsius3D (imaging), Excelsius Hub, the Pulse platform, and the newly cleared orthopedic reconstruction robot.

Manufacturing. Globus is unusual among device companies in how much it makes in-house. It runs vertically integrated manufacturing centered on its Pennsylvania campus (Audubon/Methacton area) plus facilities added through NuVasive, with significant internal capacity for machining titanium and PEEK implants and 3D-printing. This vertical integration is a deliberate strategy: it lets the company iterate designs quickly, control quality and cost, and is the main lever behind the gross-margin expansion management has been delivering (six consecutive quarters of adjusted gross-margin improvement through Q1 2026, with adjusted gross margin around 69% and a stated long-term path toward the mid-70s driven by cost and manufacturing efficiency rather than price increases).

Geographies. The business is heavily US-weighted (roughly four-fifths of revenue). International is the smaller but targeted growth vector, concentrated in EMEA and Latin America, with management framing the international opportunity as deepening density in existing countries rather than entering new ones. Every implant and robot must clear FDA in the US and CE marking / national approvals abroad, and each new system carries its own regulatory clearance - a barrier that protects the installed catalogue.

Milestones that reshaped the business: 2012 IPO; the 2017 launch of ExcelsiusGPS that created the robotics franchise; the 2023 NuVasive merger that doubled the company and made it the clear number-two in global spine; the 2025 Nevro deal that opened the neuromodulation adjacency; and the 2025 return to a debt-free balance sheet after paying off the ~$1 billion of debt inherited with NuVasive.

4. Customers

The real customer is the surgeon, even though the hospital signs the cheque. Spine and orthopedic surgeons are intensely loyal to the tools they trained on and trust - a surgeon who has done hundreds of fusions with a particular screw system and instrument tray does not switch casually, because the cost of switching is measured in operative confidence and patient safety, not dollars. Globus's entire commercial model is built around winning the surgeon: it deploys a direct and distributor sales force whose reps are physically present in the operating room for cases, handling the instrument trays, advising on sizing, and troubleshooting. That in-room presence is the relationship.

The economic buyer is the hospital or ambulatory surgery center, usually through a value-analysis committee and a purchasing/GPO (group purchasing organization) contract. Their criteria are clinical outcomes, surgeon preference (they will not stock implants their surgeons refuse to use), price, and increasingly whether a vendor can supply a broad enough range to consolidate purchasing onto fewer contracts. The sales cycle for implants is effectively continuous once a surgeon is won; the sales cycle for a robot or imaging system is a longer, capital-budget-driven negotiation that can take many months and lumps into specific quarters.

Why they choose Globus: catalogue breadth (one vendor covers most of a spine practice), fast access to new implant designs, the ExcelsiusGPS robot and its workflow, and aggressive, surgeon-embedded sales coverage. Management repeatedly attributes its double-digit US spine growth to "competitive rep recruiting" - hiring experienced reps who bring their surgeon relationships with them - layered on top of robotics pull-through and cross-selling the combined Globus + NuVasive bag.

Switching costs and lock-in run through three channels: surgeon habit and retraining, the installed base of robots (a hospital that has bought an ExcelsiusGPS is inclined to keep buying the implants designed around it), and GPO contract inertia. None of these is absolute - reps and their surgeons can be poached in either direction, which is exactly how Globus grows and also how it could lose - but together they make the revenue base sticky.

Concentration. Globus is not exposed to one or two giant customers; revenue is spread across thousands of surgeons and hundreds of hospital systems. The concentration risk is instead in the sales force: lose a productive regional sales team to a competitor and the surgeon volume can follow them out the door. Contract structure is mostly recurring per-case implant business (predictable) plus lumpier capital-equipment deals (less predictable), with the deliberate lease/rental pivot designed to convert more of the lumpy capital revenue into smoother recurring streams.

5. Competitive Landscape

Spine and broader musculoskeletal devices is an oligopoly of large diversified med-tech companies plus a few focused challengers. After the NuVasive merger, Globus sits as the clear number-two in global spine behind Medtronic. The often-cited industry shorthand is that Medtronic and Globus are the only two pure-play-scale spine franchises with double-digit global share, together roughly 40%+ of the market.

Medtronic (spine). The market leader, the company to beat. It competes on the same axes - implants plus the Mazor robotics platform plus navigation - and has vastly greater overall scale and a larger balance sheet. Globus wins against Medtronic on product iteration speed, surgeon-level service intensity, and (many surgeons argue) a more reliable robotics workflow; it loses where Medtronic's scale, hospital-enterprise relationships, and breadth across all of med-tech give it leverage.

Johnson & Johnson / DePuy Synthes. The other scale incumbent, strong in trauma (the Synthes heritage) and a meaningful spine player. Deep hospital relationships, slower on spine innovation.

Stryker. A robotics-forward competitor (Mako in joints, plus a spine and navigation presence). Strong in the operating room and in capital equipment, and a credible threat as surgical robotics blurs the lines between spine, joints, and trauma.

Zimmer Biomet. Large ortho player, stronger in joints than spine, a competitor in trauma and reconstruction adjacent to Globus's newer robot.

Alphatec (ATEC). The most direct focused challenger and the company most often cited as taking share with the same playbook Globus itself used a decade ago: aggressive rep recruiting, surgeon-centric product systems, and a lateral-access focus. Smaller, but growing fast and competing for the same reps and surgeons.

Orthofix. Smaller spine and bone-growth-stimulation player.

Neuromodulation peers (relevant to the Nevro unit). Spinal cord stimulation is dominated by Boston Scientific, Abbott, and Medtronic, all far larger in that niche than the acquired Nevro - which is part of why Nevro struggled as a standalone and why Globus is restructuring it rather than scaling it aggressively.

(Market caps are approximate peer-size references and move daily.)

Barriers to entry are real but not impregnable. A new entrant needs FDA clearances across a wide catalogue, in-house or contracted manufacturing for titanium/PEEK/3D-printed implants, a robotics platform with a track record, and - hardest of all - a surgeon-embedded sales force. Capital alone does not buy surgeon loyalty. The structural shift to watch is surgical robotics and navigation becoming table stakes, which favors the two or three players (Medtronic, Globus, Stryker) with installed robot fleets and disadvantages sub-scale implant-only competitors. Globus is strong on robotics installed base, iteration speed, and balance-sheet firepower (debt-free); it is most exposed to the same rep-poaching dynamic it uses offensively, and to the credible momentum of Alphatec.

6. Industry

Demand for spine and musculoskeletal implants is driven by demographics and disease prevalence more than by the economic cycle. The dominant tailwind is aging populations: degenerative disc disease, spinal stenosis, and osteoporotic fractures rise with age, and the over-65 cohort is growing across the developed world. Layered on top are rising obesity and diabetes (the latter feeding the painful-diabetic-neuropathy indication that Nevro targets), and a secular shift of procedures toward minimally invasive techniques and toward lower-cost ambulatory surgery centers.

Market size. Independent estimates put the global spinal implants and devices market at roughly $14-16 billion in 2025, growing in the mid-single digits (around 5-6% CAGR) toward the low-to-mid $20-billions by the early-to-mid 2030s. The broader musculoskeletal market in which Globus now plays is often sized at around $50 billion. Globus's own commentary is that the underlying US spine market grows around 3%, while it has been growing US spine at roughly 10% - meaning essentially all of its growth is share capture rather than market tailwind.

Where Globus sits in the chain. It is a vertically integrated original equipment manufacturer: it designs and largely makes its own implants and robots and sells them directly to providers, capturing more of the value chain than peers who outsource manufacturing. There is no meaningful import-substitution story here in the way there is for commodity goods; the competitive geography is about which OEM's reps and robots are in which operating rooms.

Regulation. The market is heavily gated by the FDA (510(k) clearances and, for novel devices, PMA approvals) and by CE marking and national approvals abroad. Reimbursement policy (what Medicare and private insurers pay for fusions and neuromodulation) shapes demand and is a slow-moving risk. These regulatory and reimbursement gates are part of what protects incumbents.

Cyclicality. Implant demand is relatively recession-resistant because spine surgery is largely non-deferrable for patients in severe pain, though elective volumes can soften in downturns and were sharply (temporarily) hit during COVID. The genuinely cyclical / lumpy part of Globus's business is capital-equipment (robot) sales, which depend on hospital capital budgets - which is precisely why the company is moving toward leasing.

Headwind to note: ongoing hospital pricing pressure and GPO-driven implant price erosion is a structural drag that volume and mix have to outrun.

7. Growth Triggers

All items below are forward-looking statements drawn directly from the six earnings calls.

• SCRIPT patient-specific 3D-printed implants launching. Early Q2 2026 FDA clearances for patient-matched, additively manufactured lumbar spacers and rods integrated with ExcelsiusGPS navigation, with launch planned shortly. (Q1 2026 call, May 7, 2026)

"Early in the second quarter we announced FDA clearances for patient-specific SCRIPT lumbar spacers and rods - patient-matched, additively manufactured, and integrated with ExcelsiusGPS." - CEO Keith Pfeil

• Enabling Technologies pivot to lease/rental to drive recurring implant pull-through. Management is restructuring how robots and imaging are placed, trading upfront capital revenue for recurring implant and service streams. (Q1 2026 call, May 7, 2026; reinforced across recent calls)
• Nevro return to historical revenue run-rate in late H2 2026. After a deliberate sales reorganization that depresses Nevro revenue near-term, management expects the unit to re-accelerate once recruiting and training complete in the back half of 2026. (Q1 2026 call, May 7, 2026)

"It's likely [Nevro] gets a little bit worse before it gets better... we expect a return to the historical run-rate in late in the second half of 2026." - CFO Kyle Kline

• Gross margin pathway toward the mid-70s. Six consecutive quarters of adjusted gross-margin improvement through Q1 2026, with management expecting the cadence to continue via manufacturing/cost efficiency. (Q1 2026 call, May 7, 2026; repeated theme)
• International growth via density, targeting low-to-mid-double-digit growth. Finalizing integration in H2 2026 and deepening penetration in existing EMEA/LATAM countries rather than entering new ones. (Q1 2026 call, May 7, 2026; repeated from earlier calls)
• Orthopedic reconstruction robotics extending the Excelsius platform beyond spine. FDA clearance for an ortho-reconstruction robot opens a new pull-through avenue. (referenced in 2025 calls)
• Continued US spine share gains via competitive rep recruiting and cross-selling the combined bag. Management frames double-digit US spine growth as a repeatable, share-driven engine rather than a one-off. (repeated across Q2 2025, Q3 2025, Q4 2025, Q1 2026 calls)
• NuVasive synergy capture ahead of schedule funding reinvestment. $200 million of synergies actioned, beating the target by $30 million and nearly a full year early, freeing capital for R&D (targeted to rise to 5-6% of sales). (Q4 2024 call, Feb 20, 2025; R&D target reiterated Q1 2026)

8. Key Risks

Nevro could be a value sink rather than an adjacency win. Globus bought a structurally challenged spinal-cord-stimulation business competing against Boston Scientific, Abbott, and Medtronic - all far larger in that niche. Management is deliberately shrinking Nevro revenue while it reorganizes the sales force, and openly says it will "get worse before it gets better." If the late-2026 re-acceleration does not materialize, Globus owns a declining asset in a market where it lacks scale. The deal was small (~$250 million), so the financial downside is contained, but it is a distraction-and-execution risk on top of the still-recent NuVasive integration.

"It's likely it gets a little bit worse before it gets better." - CFO Kyle Kline on Nevro, Q1 2026 call

The growth engine is share gain, not market growth - and share can flow both ways. Management is explicit that the US spine market grows ~3% while Globus grows ~10%, the gap coming from poaching competitors' reps and surgeons. That same mechanism is exactly how a focused challenger like Alphatec is taking share elsewhere. Globus's growth is therefore only as durable as its ability to keep recruiting and retaining productive sales talent; a wave of rep departures to a competitor would reverse the story quickly, and there is no contractual lock-in protecting it.

Integration overhang. The NuVasive merger doubled the company and carried "significant overlap" in implants and robotics that analysts flagged at announcement. Globus has executed the cost synergies well, but integrating two large direct sales forces risks rep attrition and dis-synergy on revenue. Q1 2025 already showed the fragility - sales actually declined that quarter on integration-related supply-chain disruption, soft enabling-tech deal closures, and international distributor timing. That was the trough, but it demonstrates the lumpiness the combined entity can produce.

Enabling Technologies revenue is lumpy and the lease pivot defers revenue. Capital-equipment deals close in irregular chunks; a soft quarter on robot placements (as happened in Q1 2025) directly dents results, and the deliberate shift from upfront sales to leasing depresses reported equipment revenue in the transition even if it improves long-run recurring economics. The market may punish the near-term optics.

Pricing and reimbursement pressure. Hospital and GPO pricing power erodes implant ASPs structurally; volume and mix must continually outrun it. A negative shift in Medicare/insurer reimbursement for fusions or neuromodulation would hit the whole industry and Globus with it. This is a slow, high-probability drag rather than a sudden shock.

Concentration in the founder and key personnel. David Paul, the founder and Executive Chairman, remains a defining figure and large holder; CEO Keith Pfeil and CFO Kyle Kline are a relatively recently configured top team. Key-person and governance dynamics around a founder-anchored company are a watch item.

9. Walk the Talk

The six calls used for this assessment: Q4 2024 (Feb 20, 2025), Q1 2025 (May 8, 2025), Q2 2025 (Aug 7, 2025), Q3 2025 (Nov 6, 2025), Q4 2025 (Feb 24, 2026), and Q1 2026 (May 7, 2026). The most recent is within 90 days of today.

The arc across these six calls is, on balance, a credible one - with one visible stumble that management owned rather than hid.

Coming out of Q4 2024 (Feb 2025), management's headline promises were concrete: NuVasive cost synergies running ahead of plan ($200 million actioned, beating the target by $30 million and nearly a year early), a return to a debt-free balance sheet by the end of Q1 2025, and a "banner year" in enabling-tech placements that would seed implant pull-through. Two of these were delivered cleanly and quickly. By the Q1 2025 (May 2025) call, the company confirmed it had paid off the remaining $450 million of NuVasive debt and was debt-free - exactly as promised, on schedule.

But Q1 2025 is also where the talk and the walk diverged for one quarter. Worldwide sales actually fell ~1.4%, which jars against the growth narrative. Management did not spin it - they attributed it specifically to softer Enabling Technology deal closures, temporary integration-related supply-chain disruption, and international distributor order timing, while pointing to underlying US spine strength as intact. Crucially, they reaffirmed full-year revenue and EPS guidance rather than cutting it, effectively betting that Q1 was a timing trough. That was a falsifiable claim.

They were vindicated. Q2 2025 (Aug 2025) delivered record non-GAAP EPS and a return to double-digit-ish growth with US spine up ~7.4% day-adjusted and Nevro contributing its first ~$95 million. Q3 2025 (Nov 2025) was stronger still - revenue up ~23%, US spine up ~10%, EPS up ~43% - and management raised full-year EPS guidance from $3.00-$3.30 to $3.75-$3.85. That is a large mid-year raise, and it is the clearest evidence that the Q1 reaffirmation was conservative rather than wishful. Q4 2025 (Feb 2026) closed the year above the raised bar (full-year sales up ~16.7%, Q4 up ~26%) and set 2026 guidance at $3.18-3.22 billion revenue and $4.30-4.40 EPS. Then at Q1 2026 (May 2026), with EPS of $1.12 against a $0.92 expectation, management raised the full-year EPS guide again to $4.70-4.80 - a second consecutive pattern of setting a guide and then beating-and-raising.

The promise-versus-outcome record:

The one thing to keep honest about is that the favorable synergy and margin story is partly a function of cost execution on an acquisition, which is the most controllable kind of promise; the harder, still-open promise is the Nevro turnaround, where management has explicitly lowered expectations ("worse before it gets better"). And the Q1 2025 wobble is a reminder that the combined company's quarter-to-quarter revenue can be lumpier than the smooth narrative suggests. Net read: this is management that has done what it said over these six calls, with a habit of guiding conservatively and then raising - the credible end of the spectrum, with Nevro the live test of whether that continues.

10. Shareholder Friendliness Index

Dividends. Globus Medical does not pay a dividend and has never paid one across the last three years. It is a growth-and-reinvestment company that has deployed capital into acquisitions (NuVasive, Nevro), internal R&D and manufacturing, and now buybacks, rather than into a payout. There is no payout-ratio story to tell because the numerator is zero.

Buybacks and dilution. On May 15, 2025 the board authorized a $500 million share repurchase program, funded entirely from cash, with no fixed expiry, explicitly framed by the CFO as a response to a "meaningful disconnect between intrinsic value and market valuation" after the share price had fallen sharply. As of the Q1 2026 call (May 7, 2026), management disclosed roughly $390 million of authorization remaining out of the $500 million - implying approximately $110 million repurchased to date under the program. The MoatMap database recorded zero buyback transactions in the trailing ~90 days, which is consistent with execution being discretionary and front-loaded into the earlier weakness rather than continuous. Set against the buyback is real dilution: the NuVasive all-stock merger issued a large block of new shares in 2023 (NuVasive holders took ~28% of the combined company), and option grants to insiders continue (David Paul received a fresh 100,000-option grant in January 2026 at a $94.15 strike). So over the full three-year window the share count rose substantially because of the merger; the buyback is a recent, modest offset to ongoing option dilution rather than a sustained shrink of the count.

Verdict: Neutral, tilting toward shareholder-friendly at the margin - no dividend and a merger that materially increased the share count, partially offset by a recently initiated, cash-funded $500m buyback being executed opportunistically into price weakness.

11. Insider Activities

Per the venue guide, US insider data comes from SEC Form 4 filings; the MoatMap database block is the spine for transactions older than ~2 weeks, cross-checked against primary filings for the most recent window.

Recent transactions (most recent first):

(Source: SEC Form 4; reflected in the MoatMap database current to 2026-06-19.)

Buys - read the signal. There are no clean open-market conviction buys in the trailing-12-month MoatMap record. The June 4-5 "Other" line items are option exercises at a $26.27 strike (deeply in-the-money against an ~$80 share price), i.e. compensation monetization, not fresh cash purchases at market. One aggregator reported a December 8, 2025 acquisition of 34,400 shares by founder/Executive Chairman David Paul at ~$25.52; that price equals an option strike, not the prevailing market price (the stock traded far higher in December 2025), so it is almost certainly an option-related acquisition rather than an open-market conviction buy, and I could not confirm a genuine open-market purchase by any insider in the window. No insider in this window made the kind of unambiguous open-market purchase that would warrant a bullish flag.

Sells - work out the why. The single clear open-market sale - Davidar's 25,000 shares at ~$80.76 on June 5, 2026 - is a textbook exercise-and-sell: the same insider exercised 25,000 options at a $26.27 strike on the same date and sold the resulting shares, capturing the spread. This is routine compensation realization, not a directional bet against the business, and is the kind of activity that typically runs through pre-arranged plans. The reason is inferable from the paired transactions (exercise then sell) even though no plan footnote is quoted here. Founder David Paul continued to hold a large position (~510,000 directly held shares reported around the June filings) and received a new 100,000-option grant in January 2026 at a $94.15 strike - a vote of continued alignment, since those options only pay off well above current levels.

Net assessment. Insider activity over the last twelve months is light, routine, and net-selling in direction but trivial in substance - dominated by option exercises and the associated tax/monetization sales by a couple of directors, with no broad-based selling and no open-market conviction buying. The activity is concentrated in two individuals doing scheduled compensation transactions, not a signal about the fundamentals. The most fundamentals-relevant insider fact is the founder's continued large holding and a fresh out-of-the-money option grant. Plain-language read: neutral - no red flag and no bullish cluster; the company's far stronger capital-allocation signal is the corporate $500m buyback (Section 10), not individual insider trades.

12. Scenarios

Bull case. The NuVasive integration, already strong on cost, proves equally strong on revenue: the combined sales force stops leaking reps and instead keeps poaching competitors' talent, and US spine compounds at low-double-digits on pure share gain for years, well above the ~3% market. The Enabling Technologies lease/rental pivot works as designed - robots go into hospitals on recurring terms, dragging high-margin implant pull-through behind them, and the new ortho-reconstruction robot opens a second platform beyond spine. SCRIPT patient-specific 3D-printed implants become a differentiated, premium-mix product that competitors cannot quickly copy because they lack the vertically integrated additive-manufacturing base. Nevro, restructured and re-staffed, returns to growth in late 2026 and turns the cheap neuromodulation acquisition into a genuine third leg. Gross margin grinds from ~69% toward the mid-70s on manufacturing efficiency, the debt-free balance sheet funds both the buyback and bolt-on deals, and Globus consolidates its position as the clear, durable number-two in global spine narrowing the gap with Medtronic.

Base case. Management delivers roughly what it has guided. US spine keeps growing high-single to low-double digits on share gains, international grinds higher on density, and the company beats-and-raises in the conservative pattern it has shown across the last six calls. Enabling Technologies stays lumpy quarter to quarter as the lease transition plays out, occasionally denting a single quarter's optics without changing the trajectory. Nevro stabilizes around late 2026 but remains a small, sub-scale unit rather than a breakout - a contained acquisition that neither hurts nor transforms. Margins improve steadily but not dramatically, the buyback is executed opportunistically into weakness, and Globus remains a well-run, founder-anchored, debt-free number-two compounding on execution rather than on any single catalyst. Nothing breaks; nothing dramatically surprises.

Bear case. The share-gain engine stalls or reverses. A focused challenger like Alphatec out-recruits Globus for reps and surgeons, and the same mechanism that drove Globus's double-digit growth runs in reverse as productive sales teams walk out the door taking their surgeon volume with them. The two-large-sales-force integration produces dis-synergy rather than cross-sell, and the Q1 2025-style lumpiness - supply disruption, soft equipment closures, distributor timing - recurs more than once instead of proving to be a one-quarter trough. Nevro never re-accelerates and becomes a chronically declining, distracting asset in a market dominated by giants. Hospital and GPO pricing pressure compresses implant ASPs faster than volume and mix can offset, capping the margin-expansion story. The lease pivot depresses reported equipment revenue more and longer than the market tolerates. In this world Globus is still a solid number-two, but it grows at the market rate rather than above it, the premium narrative deflates, and capital that went into Nevro and buybacks looks better spent elsewhere.